Jump to a section
PP405: the hair loss drug that actually does something different
If you've tried minoxidil, finasteride, dutasteride, PRP and nothing's really worked, you're not alone. Most hair loss treatments either boost blood flow or block hormones. They help some people, but if your follicles have already gone quiet, they can't do much.
That's why PP405 is getting so much attention right now. It's a completely new type of medication developed at UCLA that targets dormant follicles directly and wakes them back up. Not by blocking DHT. Not by increasing blood flow. By flipping a metabolic switch inside the stem cells themselves.
We recently covered this on our page after Pelage Pharmaceuticals dropped their latest findings at the 2026 American Academy of Dermatology conference. As Jamie explains in the video below, what makes PP405 different is that trials showed three separate effects happening at once. Not just one thing like minoxidil does.
And if you want a deeper dive into the science behind it, dermatologist Dr. David Kim does a solid breakdown of the actual mechanism here:
What is PP405?
PP405 is an experimental topical gel developed by Pelage Pharmaceuticals, a company founded in 2018 by three UCLA scientists: Bill Lowry, Heather Christofk, and Michael Jung. The name itself is a nod to their roots. "Pelage" is the French word for a coat of fur, and "405" references LA's infamous Interstate 405.
The drug started as a lab discovery roughly a decade ago. The researchers found a metabolic switch inside hair follicle stem cells that could essentially tell sleeping follicles to start growing again. First human trials kicked off in 2023 in Orange County, California, and the Phase 2a results that dropped in mid-2025 got a lot of people very excited.
What makes PP405 different from everything else on the market is its target. Current treatments either boost blood flow to existing follicles (minoxidil) or block the hormone that causes them to shrink (finasteride). PP405 goes after follicles that have already shut down. Nothing else does that.
How does PP405 actually work?
The science sounds complicated but bear with me.
Your hair follicles have stem cells in them. When you lose hair from pattern baldness, those stem cells don't actually die. They just stop doing anything. They're sitting there in your scalp, dormant. That's the bit that makes PP405 different from everything else.
As Dr. Kim puts it in the video, PP405 works by inhibiting the mitochondrial pyruvate carrier. That forces an enzyme called lactate dehydrogenase to ramp up, which increases lactate levels inside the stem cells. More lactate basically tells those sleeping cells to switch back on and start growing hair again.
Think of it like jump-starting a car. The battery isn't dead, it just needs a kick. PP405 is that kick, at a cellular level.
One crucial detail: the drug works topically and doesn't enter your bloodstream. In PP405 clinical trials, it was not detectable in blood samples. That's a big deal for people worried about systemic side effects, which have always been a concern with finasteride.
PP405 clinical trial results so far
The Phase 2a trial (registered as NCT06393452 on ClinicalTrials.gov) enrolled 78 men and women with androgenetic alopecia. Participants applied a 0.05% PP405 topical gel daily for four weeks.
The headline result: 31% of men with advanced hair loss saw a 20% or greater increase in hair density by the eight-week mark. In the placebo group, that number was zero.
But the part that got people talking wasn't just the density numbers. As Jamie broke down in his video, the trials showed three distinct effects happening at once:
- New hair growth from active follicles: two follicles could turn into three
- Reactivation of inactive follicles: waking up follicles that had stopped producing hair entirely
- Thickening of vellus hairs into terminal hairs: turning the wispy peach fuzz into proper thick hair you can actually see
That third one is what minoxidil already does. But the first two? Nothing else on the market does that. And all three happening together isn't just maintaining hair. It's reversing loss.
Results showed up faster than with conventional treatments too. Cellular activity was visible within four weeks. Compare that to minoxidil, which typically needs three to six months, or finasteride, which can take six to twelve months to show noticeable changes.
No side effects were reported during the trial, and the drug showed no systemic absorption. That said, the trial was primarily designed to test safety, not efficacy. Long-term data is still missing, and no peer-reviewed studies have been published yet. The three-month open-label extension has been completed, and Pelage presented updated data at the American Academy of Dermatology Annual Meeting in Denver this March.
PP405 vs minoxidil, finasteride, and PRP
If you've been dealing with hair loss for any length of time, you've probably tried at least one of the big three. Here's how PP405 stacks up.
Minoxidil improves blood flow to hair follicles and extends the growth phase. It works reasonably well for slowing loss and sometimes regrowing hair, but it can't reactivate follicles that have already gone dormant. You need to use it forever, and it stops working the moment you quit.
Finasteride blocks DHT, the hormone responsible for follicle miniaturisation in pattern baldness. It's effective for many men but comes with potential sexual side effects that put a lot of people off. It also doesn't do anything for already-dormant follicles.
PRP (platelet-rich plasma) involves injecting your own blood plasma into the scalp. Results are mixed, it's expensive, and you need repeat sessions. The evidence base is thin compared to minoxidil and finasteride.
PP405 does something none of these do. It goes after the stem cells directly, doesn't touch your hormones, and in the trial, participants only applied it for four weeks. No systemic side effects. If Phase 3 confirms what Phase 2a showed, this changes the conversation completely.
The caveat? Minoxidil and finasteride have decades of clinical evidence behind them. PP405 has one small Phase 2a trial. It's promising, but we need more data before anyone can call it a replacement.
When will PP405 be available?
Not soon enough. That's the short answer.
Pelage Pharmaceuticals plans to begin Phase 3 trials in 2026. These are the large-scale studies required for FDA approval. If everything goes smoothly, the new hair loss medication could receive approval somewhere between 2027 and 2029.
That's an optimistic timeline. Drug development is notoriously unpredictable. Trials can be delayed. Results can disappoint at larger scale. Regulatory reviews take time. The $120 million Pelage raised in October 2025, backed by ARCH Venture Partners and Google Ventures, gives them serious runway to see this through. But "2028 at the earliest" is probably the most realistic expectation.
There's a catch though. PP405 probably won't help if your follicles are already scarred over from years of microinflammation or fibrosis. The drug needs those stem cells to still be there, just sleeping. If the follicle is gone, there's nothing left to wake up.
What can you do right now?
PP405 is years away from pharmacy shelves. That doesn't mean you're stuck doing nothing.
First, talk to a dermatologist about current options. Minoxidil and finasteride aren't perfect, but they're proven to slow hair loss and they're available today. Starting treatment earlier gives you more follicles to work with if and when PP405 arrives.
Second, for the visual side of things, hair building fibres are a practical option that a lot of people overlook. At Hair Guru London, we sell natural cotton-based hair fibres in 14 shades that blend with your existing hair to instantly reduce the appearance of thinning. They're not a treatment. They won't regrow anything. But they give you confidence today while the science catches up. Over 30,000 customers use them, and there's a reason they're the top-selling hair fibre on TikTok Shop UK.
Third, protect what you've got. Good scalp care, stress management, proper nutrition. These basics won't reverse pattern baldness, but they help you hold onto hair for longer.
The bottom line
Look, PP405 is the first hair loss treatment in a long time that actually does something new. Not a tweak on minoxidil. Not another DHT blocker. A completely different mechanism that goes after dormant stem cells. The early data backs it up, and $120 million in funding says the money people think so too.
But it's still experimental. No peer-reviewed publications yet. No Phase 3 data. And if someone is selling you PP405 online right now, they're lying. It does not exist outside of clinical trials.
For now, use what works, protect what you've got, and keep an eye on this one. It might actually be the real deal.
Common questions about PP405
What is PP405?
It's an experimental topical gel from Pelage Pharmaceuticals that reactivates dormant hair follicle stem cells. Developed from UCLA research. Works completely differently from minoxidil or finasteride.
Does it actually work?
In the Phase 2a trial, 31% of men with advanced hair loss saw 20%+ more hair density after four weeks of use. Small study though. We need the Phase 3 data before anyone should get too excited.
When can I buy PP405?
You can't. Not yet. Phase 3 trials are planned for 2026. If those go well, FDA approval could come between 2027 and 2029. Anyone selling it online right now is selling something else.
Is PP405 better than minoxidil?
Different mechanism, faster early results, no reported side effects. But minoxidil has decades of data behind it. Too early to compare properly until the bigger trials are done.
Any side effects?
None reported so far. The drug didn't show up in blood tests either, which is a good sign. But we're still working with limited data from a small trial.
Will it work if I'm completely bald?
Maybe not. PP405 needs dormant stem cells to reactivate. If your follicles have scarred over completely, there's nothing there to wake up. It's more likely to work for people who still have some follicle activity left.